Board of Directors

Andrew Ronchi - Chief Executive Officer, Executive Director
Michael Panaccio - Acting Chairman, Non-Executive Director
Michael Winlo - Non-Executive Director
Gernot Abl - Non-Executive Director
Dr Andrew Ronchi - Chief Executive Officer, Director

B.App.Sci (Phys), PhD (Comp & Sys Eng), GAICD

Background includes 20 years clinical experience in building private practice physiotherapy clinics in Melbourne (5 clinics), working with large corporates in workplace health and elite sporting groups (MFC, St K FC).

Prior to co-founding dorsaVi in 2008, Andrew completed a PhD in Computer and Systems Engineering (RMIT), investigating the reliability and validity of wearable sensors to measure human movement.

During the past 15 years Andrew Co-Founded dorsaVi wearable sensor company, raising ~$50M through Federal and State Government grants, VC funding and listing dorsaVi Ltd on the Australian Stock Exchange (ASX). In his role as dorsaVi CEO, his passion is developing human movement technology applications and commercialising them to optimise movement and productivity, improve health and reduce injuries.

Living in San Diego, California for three years allowed Andrew to focus on understanding the US clinical and workplace market working with major corporates brands to optimise dorsaVi’s products to meet the needs of major corporate groups.

Michael Panaccio - Acting Chairman, Non-Executive Director

BSc (Hons), MBA, PhD, FAICD 

Michael Panaccio serves on the Audit and Risk Committee and the Nomination and Remuneration Committee. He was appointed to the Board on 16 May 2008. 

Michael is one of the founders of Starfish Ventures Pty Ltd, an Australian based venture capital manager. He was formerly an Investment Manager with JAFCO Investment (Asia Pacific). Prior to joining JAFCO, Michael was Head of the Department of Molecular Biology at the Victorian Institute of Animal Sciences. Michael has previously been a director of numerous technology businesses in Australia and the US including ImpediMed Ltd (resigned August 2016), SIRTeX Medical Ltd, Protagonist Therapeutic Inc and Energy Response Pty Ltd. 

With the exception of ImpediMed Ltd, no other Directorships of listed companies were held during the three years to 30 June 2017. Michael is also a director of Starfish Ventures Pty Ltd, MuriGen Therapeutics Pty Ltd, Armaron Bio Ltd, Ofidium Pty Ltd, Mimetica Pty Ltd and Cylite Pty Ltd.

Michael Winlo - Non-Executive Director

Dr Winlo is a distinguished medical professional and entrepreneur with proven leadership experience across the biotechnology, pharmaceutical and technology sectors. He is currently Chief Executive Officer and Managing Director of Emyria Limited (ASX:EMD), a clinical services and drug development company, as well as a Non-Executive Director of Nanoveu Limited (ASX:NVU), a company specialising in protective films and coatings. Dr Winlo also serves as a Director and former CEO of Linear Clinical Research, a world-class provider of early and late-stage pharmaceutical trial facilities and management services.

Prior to his role at Linear, Dr Winlo was based in Silicon Valley for five years as the Health Lead at Palantir Technologies (NYSE:PLTR), a world leading data analytics company. dorsaVi looks forward to leveraging Dr Winlo’s extensive managerial experience combined with his deep knowledge of the global healthcare landscape to propel dorsaVi’s growth strategy. 

Dr Winlo holds a Bachelor of Medicine, Bachelor of Surgery (MBBS) from the University of Western Australia and a Master of Business Administration (MBA) from Stanford University.

Gernot Abl - Non-Executive Director

Gernot Abl’s background is in law, corporate finance, and strategic consulting. Gernot has more than 20 years of entrepreneurial, business strategy, and investment experience.

Gernot has considerable commercial and investing experience and has worked with many early-stage businesses, across industries, to help commercialise, grow, and increase the value of the business for all stakeholders.

Gernot is also on the board of and advises several medium and high-growth businesses, ranging from early-stage pre-revenue companies through to early-stage ASX-listed companies.

Gernot currently serves as the Executive Director of Lithium Universe Limited (ASX:LU7).

Gernot holds a law and commerce degree with first-class honours from the University of Western Australia.